Being NICE is not the problem!

European Journal of Cancer

Volumn 45, Issue 7, 2009, Pages 1100-1102

  Jonsson, Bengt ^a  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRASTUZUMAB;

ARTICLE; CANCER RESEARCH; CANCER THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; MEDICAL DECISION MAKING; PRIORITY JOURNAL;

EID: 64049101547     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.035     Document Type: Note

References (3)

1. Mason AR, Drummond MF. Public funding of new cancer drugs: Is NICE getting nastier? Eur J Cancer [in this issue].
2. Appraising life-extending, end of life treatments. [accessed 22 January].
3. Wilking N, Jönsson B, Högberg D. Comparator report on patient access to cancer drugs in Europe. 15 January 2009 .